On November 12, 2019, the Canadian Securities Administrators (CSA) published Staff Notice 51-359 (the “Staff Notice”), highlighting inadequacies in disclosure of financial interests in M&A transactions by cannabis reporting issuers. In particular, the Staff Notice focuses on disclosure of financial interests and potential conflicts of interest arising from the personal and business relationships of insiders. This is expected, given the recent corporate governance and disclosure challenges involving a number of the cannabis reporting issuers in Canada, both large established companies and smaller industry players.
This Staff Notice follows the CSA’s guidance in Staff Notice 51-357 (see our October 10, 2018 Update, CSA Provides Guidance on Disclosure Expectations for Cannabis Issuers), which highlighted common deficiencies and best practices for issuers in the cannabis industry, focusing on the production of transparent information pertaining to financial reporting, risks and uncertainties.
Disclosure of Financial Interest in M&A Transaction Documents
The Staff Notice notes that the cannabis industry’s expansion has largely been fueled by financing from a relatively small group of players, leading to an unusually large degree of cross-ownership of financial interests amongst these parties. These financial interests may include overlapping debt and equity interests, or other business relationships. The CSA is of the view that cross-ownership results in a conflict of interest in M&A transactions and must be disclosed as the conflicts may lead investors to re-examine other variables such as price, timing and contingencies.
In response to an observation of undisclosed financial interests, the CSA has called for increased disclosure of any cross-ownership and potential conflicts of interest between parties to a transaction, whether held by the purchaser, target, or the directors or executive officers. Importantly, the Staff Notice indicates that this information is material for investors and should be disclosed even if the 10% financial interest that usually triggers disclosure under securities legislation is not met. For the CSA, this broad materiality requirement applies to any applicable disclosure document, including a circular, a listing statement, a filing statement, a prospectus and a material change report.
Independence of Board Members
The CSA also observed cannabis issuers identifying board members as being independent, without giving adequate consideration to potential conflicts of interest. Conflicts may arise from personal or business relationships with other directors and executive officers of the issuer or where a director has a direct or indirect material relationship with the issuer that interferes with a director exercising independent judgment. Issuers must consider the impact of these relationships or any other factors that may compromise independence and whether disclosure is warranted in these circumstances.
The Staff Notice also reminds issuers that the chair of the board should be an independent director, or alternatively, an independent director should be appointed as a lead director.
Finally, the CSA encourages issuers to adopt a written code of business conduct and ethics that incorporates guidance for dealing with conflicts of interest and related disclosure. Investors should be made aware of the structures that are in place to facilitate board independence.
With the heightened attention on the industry and the recent challenging capital markets leading to increasing M&A activity in the industry, cannabis reporting issuers should pay heed to the CSA guidance, as it can be expected the CSA will continue to heavily scrutinize the M&A and disclosure documents by industry participants.
Expertise
Authors
Insights
-
Cannabis
World Law Group 2020 Cannabis Guide
Victor Liu, Neil Sheehy and Danielle Levesque are contributors to the Canada section of the World Law Group 2020 Cannabis Guide. The Guide covers legislation, governing bodies, import and export… -
Cannabis
CSA Further Scrutinizes Disclosure by Cannabis Reporting Issuers
On November 12, 2019, the Canadian Securities Administrators (CSA) published Staff Notice 51-359 (the “Staff Notice”), highlighting inadequacies in disclosure of financial interests in M&A… -
Cannabis
Legal Landscape Applicable to the Regulation of Cannabis in Canada
On April 13, 2017, the Government of Canada introduced Bill C-45, the Cannabis Act, in the House of Commons. Based on the input of public health, law enforcement and justice experts, the Cannabis Act… -
Cannabis
Ontario Retail Cannabis Update… The Limited-Licence Lottery System
On December 13, the Ontario government announced significant changes to the province’s planned rollout of its retail cannabis regime. Ontario made regulation 497/18 (the “Amending Regulation”) under… -
Cannabis
Ontario Retail Cannabis Update"¦New Rules Rolled Out for Future Cannabis Retailers
The Alcohol and Gaming Commission (AGCO) released its Registrar’s Standards (the “Standards”) which provide further operational rules for cannabis retailers in Ontario. As detailed in our November… -
Cannabis
Ontario (Late to the Party) Retail Cannabis Update… With More to Come…
On October 17, 2018, Ontario enacted the Cannabis Licence Act (CLA) to permit the sale of recreational cannabis in privately owned stores. The CLA and its regulations, the Cannabis Licence Regulations…
Featured Work
-
Cannabis
Organigram Holdings Inc. to receive $124 million investment from BT DE Investments Inc.
Goodmans LLP is acting for Organigram Holdings Inc., the parent company of Organigram Inc., a leading licensed producer of cannabis, in connection with its C$124.6 million follow-on strategic equity… -
Restructuring
Ayr Wellness cross-border restructuring
Goodmans LLP acted as Canadian counsel to the Ad Hoc Committee Senior Noteholders of Ayr Wellness Inc. and Ayr Wellness Canada Holdings Inc. in connection with the negotiation and structuring of the… -
Restructuring
Wayland Group CCAA restructuring
Goodmans LLP represented the senior creditors in connection with the CCAA restructuring of Wayland Group and the acquisition of its operating business by Ring… -
Restructuring
MJardin’s restructuring proceedings
Goodmans LLP acted for KSV Restructuring Inc. (“KSV”) in respect of MJardin Group, Inc. (“MJardin” or the “Company”), a publicly traded licensed Canadian cannabis producer, in its restructuring… -
Capital Markets
Medicine Man Technologies NEO Listing
Goodmans LLP acted for Medicine Man Technologies, Inc., dba Schwazze (OTCQX: SHWZ) (NEO: SHWZ) in connection with their listing of common shares on the NEO Exchange – a tier one Canadian stock… -
Mergers and Acquisitions
Nova Net Lease REIT IPO
Goodmans LLP acted for Nova Net Lease REIT ("NOVA" or the "REIT") (CSE: NNL.U), Canada’s first Cannabis REIT, in connection with its initial public offering of 3,167,478 trust units (the "Units") at a…
News & Events
-
Banking and Financial Services
Goodmans Recognized in the Inaugural Edition of Best Law Firms - Canada 2025
Goodmans is delighted to share we are featured in the inaugural edition of Best Law Firms - Canada 2025, recognizing us as one of the country’s exceptional law firms across 40 industries and practices… -
Mergers and Acquisitions
Chambers and Partners Once Again Honours Goodmans with Top-Tier Recognition
We are delighted to announce Goodmans LLP continues to receive top-tier recognition from Chambers and Partners in the Chambers Canada 2025 Guide.Recognition from Chambers and Partners is based on… -
Banking and Financial Services
Goodmans Continues to Receive Top Tier Recognition from The Legal 500 Canada
We are pleased to announce Goodmans LLP has once again received top tier recognition from The Legal 500 Canada in their 2024 Guide released today. Recognition from The Legal 500 is based on…